SCHEMBL6444091

SCHEMBL6444091

CCOC(=O)C(C(=O)O)c1ccc(Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 6/20 0.46
CYP1A2 P05177 2/20 0.46
ABCB11 O95342 1/20 0.46
CYP3A4 P08684 1/20 0.46
TSHR P16473 1/20 0.46
HTR2A P28223 1/20 0.46
PMP22 Q01453 1/20 0.46
MMP8 P22894 1/20 0.46
FNTA P49354 3/20 0.45
FNTB P49356 3/20 0.45
PPARG P37231 5/20 0.44
FFAR1 O14842 3/20 0.43
MAPT P10636 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
CRHBP P24387 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4064086 0.92 MMP8 (0.51) PPARACYP1A2ABCB11CYP3A4TSHR
SCHEMBL5924516 0.85 MMP8 (0.46) PPARAMMP8PPARGFFAR1MAPT
SCHEMBL1041533 0.84 MMP8 (0.51) PPARACYP1A2ABCB11CYP3A4TSHR
SCHEMBL7368797 0.81 MMP8 (0.50) CYP1A2TSHRMMP8MAPTNPC1
SCHEMBL11839748 0.80 HTR2A (0.49) PPARACYP1A2ABCB11CYP3A4TSHR
SCHEMBL6444084 0.80 MEN1 (0.49) MMP8FNTAFNTBCA2CA9
SCHEMBL17466104 0.80 BRD4 (0.49) PPARACYP1A2ABCB11CYP3A4TSHR
SCHEMBL11564169 0.79 PPARA (0.46) PPARACYP1A2ABCB11CYP3A4TSHR
SCHEMBL1275691 0.77 MMP8 (0.70) TSHRMMP8CA12CA1CA2
SCHEMBL11727452 0.77 PPARA (0.49) PPARACYP1A2ABCB11CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1226128-B1 NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS HOFFMANN LA ROCHE (CH) 2005-02-23 EP disclosed
US-6716845-B2 Barbituric acid derivatives HOFFMANN-LA ROCHE INC. 2004-04-06 US disclosed
EP-1383746-A2 NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2004-01-28 EP disclosed
US-6498252-B1 Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds HOFFMANN-LA ROCHE INC. 2002-12-24 US disclosed
US-20020187991-A1 Barbituric acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 US disclosed
WO-2002079170-A2 PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THEM F. HOFFMANN-LA ROCHE AG (CH) 2002-10-10 WO disclosed
EP-1226128-A1 NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2002-07-31 EP disclosed
WO-2001025217-A1 NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020187991-A1 Barbituric acid derivatives GABBR1, GABBR2, TUBB6 PPARA 3189/4885CYP1A2 1035/4885ABCB11 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.